<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> on ventricular electrophysiological parameters, especially the dispersion of ventricular repolarization, were investigated in a canine model of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Dogs were randomized to either a control, <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>+<z:chebi fb="0" ids="2663">amiodarone</z:chebi> group </plain></SENT>
<SENT sid="2" pm="."><plain>Dogs in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>+<z:chebi fb="0" ids="2663">amiodarone</z:chebi> groups underwent 4-5 weeks of rapid ventricular pacing; dogs in the control and <z:chebi fb="0" ids="2663">amiodarone</z:chebi> groups underwent sham operation only </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> (20 mg/kg per day) was administered orally, beginning on postoperative Day 1, in the treatment groups; ventricular electrophysiological variables were evaluated 4-5 weeks after rapid pacing or sham operation </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> dogs, the transmural dispersion ventricular repolarization time (TDVRT) increased significantly </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> significantly decreased the TDVRT in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> dogs </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> threshold (VFT) decreased in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> group </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> increased the VFT in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> dogs </plain></SENT>
<SENT sid="8" pm="."><plain>The TDVRT increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> dogs, but <z:chebi fb="0" ids="2663">amiodarone</z:chebi> decreased TDVRT and increased VFT in these dogs </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest a beneficial effect of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> on malignant <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and may provide the basis for its use in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients </plain></SENT>
</text></document>